control group:Pembrolizumab

3 trials

Sponsors

LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Hebei General Hospital

Conditions

head and neck squamous cell carcinomanon-small lung cancer cell, NSCLC

Early Phase 1

The Clinical study of Yiqi Jiedu compound combined with Pembrolizumab in the treatment of non-small cell lung cancer patients with chemotherapy resistance

RecruitingChiCTR2000036977

LongHua Hospital, Shanghai University of Traditional Chinese Medicinenon-small lung cancer cell, NSCLC

Start: 2020-10-01Updated: 2020-09-28

The Clinical study of Yiqi Jiedu compound combined with Pembrolizumab in the treatment of non-small cell lung cancer patients with chemotherapy resistance

RecruitingITMCTR2000003721

LongHua Hospital, Shanghai University of Traditional Chinese Medicinenon-small lung cancer cell, NSCLC

Start: 2020-10-01Updated: 2023-02-20

Phase 2

Clinical Study of iodine-125 Seed Implantation Combined with immunotherapy in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

RecruitingChiCTR2300078050

Hebei General Hospitalhead and neck squamous cell carcinoma

Start: 2023-11-28Updated: 2023-12-03